Hikmettullah Batgi (Hikmetullah Batgi)

Publication Activity (10 Years)

Years Active: 2019-2021
Publications (10 Years): 4

Top Topics

Multiple Myeloma

Radiation Therapy

Hodgkin Lymphoma

Top Venues

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Turkish journal of medical sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Hikmettullah Batgi, Başcı Semih, Mehmet Sinan Dal, Merih Kızıl Çakar, Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Nurgül Özcan, Ali Kılınç, Alparslan Merdin, Jale Yıldız, Mehmet Bakırtaş, Derya Şahin, Tahir Darçın, Dicle İskender, Nuran Ahü Baysal, Fevzi Altuntaş
Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience Turkish journal of medical sciences 51 (2) (2021)
Hikmettullah Batgi, Mehmet Sinan Dal, Alparslan Merdin, Merih Kızıl Çakar, Tuğçe Nur Yiğenoğlu, Fevzi Altuntaş
A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 26 (6) (2020)
Hikmettullah Batgi, Alparslan Merdin, Mehmet Sinan Dal, Merih Kızıl Çakar, Jale Yıldız, Semih Başçı, Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Tahir Darçın, Derya Şahin, Mehmet Bakırtaş, Ayşegül Tetik, Dicle İskender, Fevzi Altuntaş
The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 26 (8) (2020)
Alparslan Merdin, Merih Kızıl Çakar, Mehmet Sinan Dal, Duygu Mert, Jale Yıldız, Semih Başçı, Mehmet Bakırtaş, Tahir Darçın, Derya Şahin, Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Hikmettullah Batgi, Ayşegül Tetik, Dicle İskender, Fevzi Altuntaş
Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 26 (4) (2019)